About Transcription factor E2F5
Transcription factor E2F5 (E2F5) is a protein
from Homo sapiens identified by UniProt accession
Q15329, 346 residues long.
MolForge cross-references it against 0 known binders and
97 disease associations.
Target properties
| Protein name | Transcription factor E2F5 |
|---|
| UniProt accession | Q15329 |
|---|
| Gene | E2F5 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 346 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (97)
Diseases linked to this target (Open Targets).
- coronary artery disease · score 0.26
- endometrial cancer · score 0.25
- head and neck squamous cell carcinoma · score 0.21
- hepatocellular carcinoma · score 0.09
- neoplasm · score 0.09
- esophageal squamous cell carcinoma · score 0.07
- oral squamous cell carcinoma · score 0.06
- cryptorchidism · score 0.05
- glioblastoma multiforme · score 0.05
- 46,XY complete gonadal dysgenesis · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q15329-F1 | alphafold | PREDICTED | 70.87 | — |
Amino-acid sequence (346 residues)
MAAAEPASSG QQAPAGQGQG QRPPPQPPQA QAPQPPPPPQ LGGAGGGSSR HEKSLGLLTT KFVSLLQEAK DGVLDLKAAA DTLAVRQKRR IYDITNVLEG IDLIEKKSKN SIQWKGVGAG CNTKEVIDRL RYLKAEIEDL ELKERELDQQ KLWLQQSIKN VMDDSINNRF SYVTHEDICN CFNGDTLLAI QAPSGTQLEV PIPEMGQNGQ KKYQINLKSH SGPIHVLLIN KESSSSKPVV FPVPPPDDLT QPSSQSLTPV TPQKSSMATQ NLPEQHVSER SQALQQTSAT DISSAGSISG DIIDELMSSD VFPLLRLSPT PADDYNFNLD DNEGVCDLFD VQILNY
Explore Transcription factor E2F5 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets